Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)
| Autor: | Hiroyuki Takei, Junichi Koh, Kazuhiko Sato, Hitoshi Tsuda, Masafumi Kurosumi, Tsuyoshi Saito, Kimito Suemasu, Katsuhiko Okubo, Toshio Tabei, Kenichi Inoue |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Time Factors medicine.medical_treatment Antineoplastic Agents Breast Neoplasms chemistry.chemical_compound Breast cancer Exemestane Internal medicine Humans Medicine Adverse effect Mastectomy Neoadjuvant therapy Aged Aged 80 and over business.industry Cancer Middle Aged medicine.disease Neoadjuvant Therapy Surgery Androstadienes Postmenopause Treatment Outcome Receptors Estrogen Tolerability chemistry Female Receptors Progesterone business Progressive disease |
| Zdroj: | Breast Cancer Research and Treatment. 107:87-94 |
| ISSN: | 1573-7217 0167-6806 |
| Popis: | This multicenter phase II trial evaluated the efficacy and tolerability of 4 months of neoadjuvant exemestane in 44 postmenopausal patients with estrogen receptor (ER)-positive and/or progesterone receptor-positive, stage II to IIIB breast cancer measuringor=3 cm. Pathological response was assessed by a central review board using response criteria proposed by the Japanese Breast Cancer Society. Clinical response [complete or partial response (PR)] was assessed by caliper, mammography, or ultrasound. Rates of breast-conserving surgery (BCS) and adverse events were also evaluated. A pathological response was observed in 13 (43%) of 30 patients who underwent surgery at 4 months. Fourteen patients were excluded from the pathological analysis: eight continued exemestane because of PR or stable disease (SD) at 4 months, three underwent chemotherapy because of progressive disease, and three underwent surgery within 2 months because of adverse events. A clinical response was seen in 27 (66%) of 41 evaluable patients. BCS was performed in 27 (90%) of 30 patients who underwent surgery at 4 months. Of the ten patients eligible for mastectomy at baseline, six chose to continue exemestane treatment without surgery because of a PR or SD at 4 months. Adverse events, most of which were grade 1, occurred inor=10% of patients. These results suggest that neoadjuvant exemestane treatment is effective and well tolerated in postmenopausal women with ER-positive breast cancer. Further studies are required to determine the optimal duration of neoadjuvant treatment and to identify response criteria that can more accurately predict long-term outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink